Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody that targets cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) and antagonizes CTLA-4–mediated inhibitory immune checkpoints, thereby enhancing immune cell activation, Zalifrelimab is widely used in immuno-oncology research to study immune checkpoint blockade and antitumor immune responses.

In functional assays, Zalifrelimab inhibited the interaction between CTLA-4 and CD80/CD86, increasing antigen-specific T-cell reactivity within a concentration range of 0.1 to 100 μg/mL [1].

In Cynomolgus macaques, intravenous (i.v.) administration of Zalifrelimab (10 mg/kg, given on days 1 and 29) was evaluated for tolerance and immunological response. The treatment enhanced vaccine-mediated antigen-specific immune responses in this model. In research involving patients with recurrent or metastatic cervical cancer, the combination of Zalifrelimab and Balstilimab (anti-PD-1) exhibited antitumor activity, characterized by durable responses in the target populations [1][2].

Human

Monoclonal

Unconjugated